NRC.F · Neuronetics, Inc

-

Please sign in to comment on NRC.F

1 Comment

Admin

4 years, 1 month ago

Neuronetics, Inc is currently in a long term uptrend where the price is trading 17.2% above its 200 day moving average.

From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.6.

Neuronetics, Inc's total revenue sank by 10.2% to $16M since the same quarter in the previous year.

Its net income has increased by 51.6% to $-4M since the same quarter in the previous year.

Finally, its free cash flow grew by 73.1% to $-2M since the same quarter in the previous year.

Based on the above factors, Neuronetics, Inc gets an overall score of 4/5.

Exchange	F
CurrencyCode	EUR
ISIN	US64131A1051
Sector	Healthcare
Industry	Diagnostics & Research

PE Ratio	None
Target Price	17.5
Beta	1.98
Market Cap	267M
Dividend Yield	None

ABOUT

Neuronetics, Inc

Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

NRC.F · Neuronetics, Inc

-

Neuronetics, Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Neuronetics, Inc using a moving average strategy